BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Policy

  Gilead’s Strong Financials Marred by $1.25B ViiV Patent Settlement

  This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute involving the HIV drug dolutegravir.

  February 2, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Why Second Guessing Yourself at Work Bad and How to Stop

  Second guessing yourself at each stage of decision-making is a bad practice. Therefore, learning how to avoid it becomes crucial and this article will help you with that.

  February 2, 2022

   · 

  5 min read

   · 

  Karen Walpole
• 

  Business

  Sandoz Set Up for Future Growth as it Preens in the Display Window

  Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.

  February 2, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Report: External Partnerships, Infectious Disease Research Drives Biopharma Innovation

  In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.

  February 2, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Anavex Responds to Rett Trial Controversy, Blames CRO

  The press release has been shrouded with controversy, and the company’s stock fell 16% despite the seemingly optimistic results.

  February 2, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie Leans on Skyrizi, Rinvoq as Humira Rides off the Patent Cliff

  Humira will begin to lose exclusivity in 2023, and numerous biosimilar competitors are waiting to break in on the drug’s lucrative market.

  February 2, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Regeneron, Sanofi Blockbuster Dupixent Scores Points in 5 More Indications

  Regeneron and Sanofi’s anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.

  February 2, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Paxlovid Deal Details and Assessment of Pandemic Response Begins

  Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.

  February 2, 2022

   · 

  7 min read

   · 

  Mark Terry
• 

  Policy

  Pfizer Submits Much-Anticipated COVID-19 Vaccine for Children Under 5

  Finally, Pfizer has submitted the request to FDA to grant emergency use status to their vaccine for children. Here’s everything you should know about the vaccine.

  February 2, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Organon Declares International Women’s Day a Corporate Holiday

  The global women’s health company took another step in its initiative to encourage healthcare equality for women by declaring March 8, International Women’s Day, an annual holiday.

  February 2, 2022

   · 

  2 min read

   · 

  Claudia Beezhold